Stockhouse Research: DirectCash craziness and Cipher generic drug battles

Drug company Cipher Pharmaceuticals suffered a stock plunge today when they became embroiled in a patent battle with Watson Laboratories over their Absorica product. Bullboarders seem bullish on the news, stating the application filed by Watson looking for an early generic version of the drug, should fail, with the stock likely to bounce back.

But the madness surrounding the DirectCash Payments share price puts Cipher in the shade. DirectCash plummeted 24% this morning with no seeming reason behind the run. Trading was halted, but what happened to cause the drop has company execs shrugging.


Most Viewed Company Pages:

1. DirectCash Payments (T.DCI) (new)
2. Blackberry (T.BB) (6)
3. Fission Uranium (V.FCU) (5)
4. Wi-Lan Inc. (T.WIN) (3)
5. Canada Carbon (V.CCB) (4)

Most Read Bullboards:

1. Wi-Lan Inc. (T.WIN) (2)
2. DirectCash Payments (T.DCI) (new)
3. Mart Resources (V.MMT) (1)
4. Cipher Pharmaceuticals (T.DND) (new)
5. Blackberry (T.BB) (5)

Most Read Stories:

1. Robert Friedland takes dig at Teck
2. Strata-X gears up for oil and gas drilling
3. Pfizer yet to comment on Colombian Viagra penis amputation story
4. Cameco facing tax evasion allegations
5. Sphere Resources soars 67% on project update

Most Read Press Releases:

1. Ascot Resources intersects 10 meters of 33.66 grams per tonne gold
2. Badger Daylighting Ltd September cash dividend
3. BMO mobile banking survey 70% of smartphone users